SCHEMBL6492291

SCHEMBL6492291

O=C1c2ccccc2-c2c1cc(O)c1ccsc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 4/20 0.50
MCL1 Q07820 4/20 0.50
TERT O14746 4/20 0.49
PKLR P30613 3/20 0.44
MAPT P10636 6/20 0.42
MAOA P21397 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 5/20 0.41
MAPK1 P28482 4/20 0.41
HPGD P15428 3/20 0.41
ALOX15 P16050 3/20 0.41
HSD17B10 Q99714 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
MAOB P27338 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6503595 0.77 TTR (0.44) BCL2MCL1TERTMAPTMEN1
SCHEMBL6169603 0.76 MCL1 (0.61) BCL2MCL1PKLRMAPTMAOA
SCHEMBL11809264 0.73 MCL1 (0.65) BCL2MCL1PKLRMAPTMAOA
SCHEMBL2769983 0.69 BCL2 (1.00) BCL2MCL1TERTPKLRMAPT
SCHEMBL2023599 0.69 KMT2A (0.53) BCL2MCL1MAPTMEN1KMT2A
SCHEMBL555230 0.67 BCL2 (1.00) BCL2MCL1PKLRMAPTMAOA
SCHEMBL29384381 0.67 BCL2 (1.00) BCL2MCL1PKLRMAPTMAOA
Xanthopurpurin SCHEMBL1426707 0.67 BCL2 (1.00) BCL2MCL1PKLRMAPTMAOA
Xanthopurpurin SCHEMBL29407313 0.67 BCL2 (1.00) BCL2MCL1PKLRMAPTMAOA
SCHEMBL29388375 0.67 BCL2 (1.00) BCL2MCL1PKLRMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881850-B2 Heterocyclically annellated indenochromene derivatives RODENSTOCK GMBH (DE) 2005-04-19 US disclosed
US-20040092743-A1 Heterocyclically annellated indenochromene derivatives OPTISCHE WERKE G. RODENSTOCK 2004-05-13 US disclosed
US-6660727-B1 Photochromic heterocyclically anellated indenochromene compounds RODENSTOCK GMBH (DE) 2003-12-09 US disclosed
EP-1144416-A1 HETEROCYCLICALLY ANELLATED INDENOCHROMENE DERIVATIVES Optische Werke G. Rodenstock (DE) 2001-10-17 EP disclosed
WO-2001034609-A1 HETEROCYCLICALLY ANELLATED INDENOCHROMENE DERIVATIVES OPTISCHE WERKE G. RODENSTOCK (DE) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092743-A1 Heterocyclically annellated indenochromene derivatives ALDH1A2, INF2, CYP1B1 BCL2 3742/4885MCL1 3858/4885TERT 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.